We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Will Flagship Impella Drive ABIOMED's (ABMD) Q3 Earnings?
Read MoreHide Full Article
ABIOMED, Inc. is scheduled to release its third-quarter fiscal 2019 results on Jan 31. We believe the company is set to gain from its flagship Impella product line.
Q2 Results at a Glance
ABIOMED reported second-quarter fiscal 2019 earnings of 81 cents per share, which surpassed the Zacks Consensus Estimate by 11%. Adjusted earnings skyrocketed 84.1% from the year-ago quarter’s tally.
Revenues came in at $181.8 million, outpacing the Zacks Consensus Estimate of $175.3 million. The top line also increased 36.9% from the prior-year quarter’s figure.
In the trailing three quarters, ABIOMED delivered average positive earnings surprise of 18.8%.
The Zacks Consensus Estimate for ABIOMED’s third-quarter earnings is pegged at 94 cents, mirroring 34.3% improvement year over year. The same for revenues stands at $200.6 million, reflecting an increase of 30.2% year over year.
Let’s see how things are shaping up prior to the earnings release.
Impella Likely to Drive Q3 Results
ABIOMED’s flagship product line, Impella, has consistently provided a boost to the top line. Impella is a support system of percutaneous, catheter-based devices offering hemodynamic support to the heart. In the last reported quarter, Impella contributed 96.4% to ABIOMED’s net sales. Meanwhile, U.S. Impella revenues rose 38% to $175.3 million on a year-over-year basis.
Notably, ABIOMED has been progressing well with SmartAssist, Impella Connect, IQ Impella Quality Assurance Database, cVAD and NCSI platforms. Furthermore, there is a growing physician awareness on Impella's ability to protect against acute kidney injury.
Other Factors at Play
Preliminary Results for Q3
ABIOMED recently announced preliminary results for third-quarter fiscal 2019. Revenues are anticipated to come in at $200.6 million, up 30% year over year.
ABIOMED expects to see a solid contribution from its core Impella product line. Per management, domestic revenues from Impella products are expected to surge 27% on a year-over-year basis to $165.5 million. In the quarter under review, U.S. patient usage is anticipated to improve 24%. Outside the United States, Impella product revenues are projected to be $27.5 million, up 59% year over year.
The quarter also witnessed strong sales in Germany and Japan. Moreover, ABIOMED’s Impella utilization is accelerating at a remarkable pace, with an increasing number of hospitals and customer sites purchasing the same.
These apart, ABIOMED raised its fiscal 2019 guidance. For the fiscal year, the company expects revenues to be approximately $780 million, up from $765-$770 million projected earlier. This shows an increase of 31% from the prior-year figure.
Lucrative Market Trends for CHD
We believe that ABIOMED will have a strong foothold in the coronary heart diseases market in the United States. Increasing popularity of ABIOMED’s products to reduce patient recovery time is saving hospitalization costs.
What Does Our Model Say?
Our proven model clearly indicates that a stock needs to have both — a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) — to deliver a positive earnings surprise. This is precisely the case here.
Earnings ESP: ABIOMED has an Earnings ESP of +2.60%. You can uncover the best stocks to buy or sell before they’re reported with our Earnings ESP Filter.
Zacks Rank: ABIOMED carries a Zacks Rank #2.
Please note that we caution against stocks with a Zacks Rank #4 or 5 (Sell rated) going into the earnings announcement, especially when the company is seeing negative estimate revision.
Stocks Worth a Look
Here are a few medical stocks worth considering as they also have the right combination of elements to post an earnings beat this quarter.
Intuitive Surgical, Inc. (ISRG - Free Report) has an Earnings ESP of +2.63% and a Zacks Rank #2.
DexCom (DXCM - Free Report) has an Earnings ESP of +8.93% and a Zacks Rank #2.
More Stock News: This Is Bigger than the iPhone!
It could become the mother of all technological revolutions. Apple sold a mere 1 billion iPhones in 10 years but a new breakthrough is expected to generate more than 27 billion devices in just 3 years, creating a $1.7 trillion market.
Zacks has just released a Special Report that spotlights this fast-emerging phenomenon and 6 tickers for taking advantage of it. If you don't buy now, you may kick yourself in 2020.
Image: Bigstock
Will Flagship Impella Drive ABIOMED's (ABMD) Q3 Earnings?
ABIOMED, Inc. is scheduled to release its third-quarter fiscal 2019 results on Jan 31. We believe the company is set to gain from its flagship Impella product line.
Q2 Results at a Glance
ABIOMED reported second-quarter fiscal 2019 earnings of 81 cents per share, which surpassed the Zacks Consensus Estimate by 11%. Adjusted earnings skyrocketed 84.1% from the year-ago quarter’s tally.
Revenues came in at $181.8 million, outpacing the Zacks Consensus Estimate of $175.3 million. The top line also increased 36.9% from the prior-year quarter’s figure.
In the trailing three quarters, ABIOMED delivered average positive earnings surprise of 18.8%.
ABIOMED, Inc. Price and Consensus
ABIOMED, Inc. Price and Consensus | ABIOMED, Inc. Quote
Which Way Are Q3 Estimates Treading?
The Zacks Consensus Estimate for ABIOMED’s third-quarter earnings is pegged at 94 cents, mirroring 34.3% improvement year over year. The same for revenues stands at $200.6 million, reflecting an increase of 30.2% year over year.
Let’s see how things are shaping up prior to the earnings release.
Impella Likely to Drive Q3 Results
ABIOMED’s flagship product line, Impella, has consistently provided a boost to the top line. Impella is a support system of percutaneous, catheter-based devices offering hemodynamic support to the heart. In the last reported quarter, Impella contributed 96.4% to ABIOMED’s net sales. Meanwhile, U.S. Impella revenues rose 38% to $175.3 million on a year-over-year basis.
Notably, ABIOMED has been progressing well with SmartAssist, Impella Connect, IQ Impella Quality Assurance Database, cVAD and NCSI platforms. Furthermore, there is a growing physician awareness on Impella's ability to protect against acute kidney injury.
Other Factors at Play
Preliminary Results for Q3
ABIOMED recently announced preliminary results for third-quarter fiscal 2019. Revenues are anticipated to come in at $200.6 million, up 30% year over year.
ABIOMED expects to see a solid contribution from its core Impella product line. Per management, domestic revenues from Impella products are expected to surge 27% on a year-over-year basis to $165.5 million. In the quarter under review, U.S. patient usage is anticipated to improve 24%. Outside the United States, Impella product revenues are projected to be $27.5 million, up 59% year over year.
The quarter also witnessed strong sales in Germany and Japan. Moreover, ABIOMED’s Impella utilization is accelerating at a remarkable pace, with an increasing number of hospitals and customer sites purchasing the same.
These apart, ABIOMED raised its fiscal 2019 guidance. For the fiscal year, the company expects revenues to be approximately $780 million, up from $765-$770 million projected earlier. This shows an increase of 31% from the prior-year figure.
Lucrative Market Trends for CHD
We believe that ABIOMED will have a strong foothold in the coronary heart diseases market in the United States. Increasing popularity of ABIOMED’s products to reduce patient recovery time is saving hospitalization costs.
What Does Our Model Say?
Our proven model clearly indicates that a stock needs to have both — a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) — to deliver a positive earnings surprise. This is precisely the case here.
Earnings ESP: ABIOMED has an Earnings ESP of +2.60%. You can uncover the best stocks to buy or sell before they’re reported with our Earnings ESP Filter.
Zacks Rank: ABIOMED carries a Zacks Rank #2.
Please note that we caution against stocks with a Zacks Rank #4 or 5 (Sell rated) going into the earnings announcement, especially when the company is seeing negative estimate revision.
Stocks Worth a Look
Here are a few medical stocks worth considering as they also have the right combination of elements to post an earnings beat this quarter.
Intuitive Surgical, Inc. (ISRG - Free Report) has an Earnings ESP of +2.63% and a Zacks Rank #2.
Illumina, Inc. (ILMN - Free Report) has an Earnings ESP of +0.32% and a Zacks Rank #2. You can see the complete list of today’s Zacks #1 Rank stocks here.
DexCom (DXCM - Free Report) has an Earnings ESP of +8.93% and a Zacks Rank #2.
More Stock News: This Is Bigger than the iPhone!
It could become the mother of all technological revolutions. Apple sold a mere 1 billion iPhones in 10 years but a new breakthrough is expected to generate more than 27 billion devices in just 3 years, creating a $1.7 trillion market.
Zacks has just released a Special Report that spotlights this fast-emerging phenomenon and 6 tickers for taking advantage of it. If you don't buy now, you may kick yourself in 2020.
Click here for the 6 trades >>